HC Wainwright Initiates Coverage on Innate Pharma (IPHYF)
Equities researchers at HC Wainwright started coverage on shares of Innate Pharma (NASDAQ:IPHYF) in a note issued to investors on Wednesday. The brokerage set a “buy” rating on the stock.
Separately, Zacks Investment Research raised Innate Pharma from a “sell” rating to a “hold” rating in a report on Tuesday, May 9th.
Shares of Innate Pharma (IPHYF) opened at 12.96 on Wednesday. The company’s 50-day moving average price is $12.54 and its 200-day moving average price is $12.40. The stock has a market cap of $699.74 million and a PE ratio of 48.18. Innate Pharma has a 52-week low of $10.72 and a 52-week high of $16.55.
COPYRIGHT VIOLATION WARNING: “HC Wainwright Initiates Coverage on Innate Pharma (IPHYF)” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/hc-wainwright-initiates-coverage-on-innate-pharma-iphyf/1535068.html.
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.